Wednesday 19 July 2017

Seven Major Markets Slated to See a Rise in 23.5% Diagnosed Cases of Bladder Cancer by 2025

ResearchMoz added Latest Research Report titled " EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025 " to it's Large Report database.

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025

Summary

Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide. The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease significantly more common in men than women. The majority of bladder cancer cases are among older individuals, with the median age at diagnosis being 73 years; because of this, the comorbidities associated with bladder cancer are similar to conditions typically occurring in older age, and therefore are not specific to bladder cancer.

GlobalData epidemiologists forecast that by 2025, the 7MM are expected to have 289,623 diagnosed incident cases of bladder cancer, representing a 23.5% increase from the number of incident cases in 2015 (234,581 incident cases).

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=915866

In 2015, the 7MM had 873,493 five-year diagnosed prevalent cases of bladder cancer and GlobalData epidemiologists forecast that by 2025, this number will grow to 1,094,707 five-year diagnosed prevalent cases at an Annual Growth Rate (AGR) of 2.53%.

This forecast is supported by at least 10 years of historical data obtained from country-specific studies published by the World Health Organizations (WHO) International Agency for Research on Cancer (IARC), the National Cancer Institutes (NCI) Surveillance, Epidemiology, and End Results (SEER) program, the European Cancer Registrys fifth database registry (EUROCARE-5), the Center for Cancer Control and Information Services, National Cancer Center (CCCIS, NCC) in Japan, as well as country-specific cancer registries. Another major strength of this analysis is that GlobalData epidemiologists were able to forecast incident cases of bladder cancer in the 7MM by age, sex, and stage at diagnosis. Furthermore, the forecast methodology was consistent across all markets, thereby allowing for a meaningful global comparison.

Browse more details @ http://www.researchmoz.us/epicast-report-bladder-cancer-epidemiology-forecast-to-2025-report.html

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Epidemiology 7
2.1 Disease Background 7
2.2 Risk Factors and Comorbidities 7
2.3 Global Trends 8
2.3.1 Incidence 9
2.3.2 Relative Survival 11
2.4 Forecast Methodology 12
2.4.1 Sources Used Tables 12
2.4.2 Forecast Assumptions and Methods 16
2.4.3 Sources Not Used 20
2.5 Epidemiological Forecast for Bladder Cancer (2015-2025) 21
2.5.1 Diagnosed Incident Cases of Bladder Cancer 21
2.5.2 Age-Specific Diagnosed Incident Cases of Bladder Cancer 22
2.5.3 Sex-Specific Diagnosed Incident Cases of Bladder Cancer 24
2.5.4 Age-Standardized Diagnosed Incidence Rates of Bladder Cancer 26
2.5.5 Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis 27
2.5.6 Five-Year Diagnosed Prevalent Cases of Bladder Cancer 27
2.6 Discussion 29
2.6.1 Epidemiological Forecast Insight 29
2.6.2 Limitations of the Analysis 30
2.6.3 Strengths of the Analysis 31

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

No comments:

Post a Comment